{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:14:14Z","timestamp":1793726054753,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-023-01155-5","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T23:22:36Z","timestamp":1690932156000},"page":"3605-3617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Increased serum soluble interleukin-2 receptor levels in dermatomyositis are associated with Th17\/Treg immune imbalance"],"prefix":"10.1007","volume":"23","author":[{"given":"Yuhuan","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"issue":"1","key":"1155_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):86.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"1155_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/BOR.0000000000000328","volume":"28","author":"S Rothwell","year":"2016","unstructured":"Rothwell S, Lamb JA, Chinoy H. New developments in genetics of myositis. Curr Opin Rheumatol. 2016;28(6):651\u20136.","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"1155_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrrheum.2018.48","volume":"14","author":"FW Miller","year":"2018","unstructured":"Miller FW, Lamb JA, Schmidt J, Nagaraju K. Risk factors and disease mechanisms in myositis. Nat Rev Rheumatol. 2018;14(5):255\u201368.","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"1155_CR4","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, et al. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955\u201364.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1155_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","volume":"17","author":"A Selva-O'Callaghan","year":"2018","unstructured":"Selva-O\u2019Callaghan A, Pinal-Fernandez I, Trallero-Aragu\u00e1s E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816\u201328.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1155_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","volume":"52","author":"M Satoh","year":"2017","unstructured":"Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol. 2017;52(1):1\u201319.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4856","key":"1155_CR7","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1126\/science.3131876","volume":"240","author":"KA Smith","year":"1988","unstructured":"Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988;240(4856):1169\u201376.","journal-title":"Science"},{"issue":"10","key":"1155_CR8","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","volume":"18","author":"R Spolski","year":"2018","unstructured":"Spolski R, Li P, Leonard WJ. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat Rev Immunol. 2018;18(10):648\u201359.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"1155_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.41451","volume":"5","author":"J He","year":"2022","unstructured":"He J, Chen J, Miao M, et al. Efficacy and safety of low-dose interleukin 2 for primary sj\u00f6gren syndrome: a randomized clinical trial. JAMA Netw Open. 2022;5(11): e2241451.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1155_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/annrheumdis-2014-206506","volume":"74","author":"JY Humrich","year":"2015","unstructured":"Humrich JY, von Spee-Mayer C, Siegert E, et al. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann Rheum Dis. 2015;74(4):791\u20132.","journal-title":"Ann Rheum Dis"},{"key":"1155_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","volume":"58","author":"M Rosenzwajg","year":"2015","unstructured":"Rosenzwajg M, Churlaud G, Mallone R, et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun. 2015;58:48\u201358.","journal-title":"J Autoimmun"},{"issue":"8","key":"1155_CR12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.7326\/0003-4819-113-8-619","volume":"113","author":"LA Rubin","year":"1990","unstructured":"Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990;113(8):619\u201327.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1155_CR13","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.coi.2011.08.003","volume":"23","author":"W Liao","year":"2011","unstructured":"Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol. 2011;23(5):598\u2013604.","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"1155_CR14","first-page":"142","volume":"126","author":"J Chen","year":"2020","unstructured":"Chen J, Jin Y, Li C, et al. Evaluation of soluble CD25 as a clinical and autoimmune biomarker in primary Sj\u00f6gren\u2019s syndrome. Clin Exp Rheumatol. 2020;126(4):142\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"1155_CR15","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1177\/0961203318760993","volume":"27","author":"RJ Zhang","year":"2018","unstructured":"Zhang RJ, Zhang X, Chen J, et al. Serum soluble CD25 as a risk factor of renal impairment in systemic lupus erythematosus: a prospective cohort study. Lupus. 2018;27(7):1100\u20136.","journal-title":"Lupus"},{"issue":"10","key":"1155_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223897","volume":"14","author":"LEM Eurelings","year":"2019","unstructured":"Eurelings LEM, Miedema JR, Dalm V, et al. Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis. PLoS ONE. 2019;14(10): e0223897.","journal-title":"PLoS ONE"},{"issue":"5","key":"1155_CR17","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1080\/14397595.2017.1416739","volume":"28","author":"T Handa","year":"2018","unstructured":"Handa T, Matsui S, Yoshifuji H, et al. Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease. Mod Rheumatol. 2018;28(5):838\u201344.","journal-title":"Mod Rheumatol"},{"key":"1155_CR18","doi-asserted-by":"publisher","first-page":"6243019","DOI":"10.1155\/2020\/6243019","volume":"2020","author":"L He","year":"2020","unstructured":"He L, Shu X, Liu X, et al. Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity. Mediators Inflamm. 2020;2020:6243019.","journal-title":"Mediators Inflamm"},{"issue":"7","key":"1155_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344\u20137.","journal-title":"N Engl J Med"},{"issue":"8","key":"1155_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403\u20137.","journal-title":"N Engl J Med"},{"key":"1155_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/472624","volume":"2014","author":"A Tournadre","year":"2014","unstructured":"Tournadre A, Dubost JJ, Soubrier M, et al. Soluble IL-2 receptor: a biomarker for assessing myositis activity. Dis Markers. 2014;2014: 472624.","journal-title":"Dis Markers"},{"issue":"3","key":"1155_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00296-010-1692-y","volume":"32","author":"P Mielnik","year":"2012","unstructured":"Mielnik P, Chwalinska-Sadowska H, Wiesik-Szewczyk E, Maslinski W, Olesinska M. Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity. Rheumatol Int. 2012;32(3):639\u201343.","journal-title":"Rheumatol Int"},{"issue":"2 Suppl","key":"1155_CR23","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1097\/CCM.0b013e3181c98d21","volume":"38","author":"M Levi","year":"2010","unstructured":"Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38(2 Suppl):S26-34.","journal-title":"Crit Care Med"},{"key":"1155_CR24","doi-asserted-by":"crossref","unstructured":"Zheng CS, Qin XJ, Ni H, Chen RY, Liu JL, Wang WH. Evaluation of disease activity of systemic lupus erythematosus by D-dimer combined with red blood cell distribution width. Clin Lab. 2021;67 (9)","DOI":"10.7754\/Clin.Lab.2021.210118"},{"issue":"1","key":"1155_CR25","doi-asserted-by":"publisher","first-page":"16903","DOI":"10.1038\/s41598-021-96349-w","volume":"11","author":"L Xue","year":"2021","unstructured":"Xue L, Tao L, Li X, et al. Plasma fibrinogen, D-dimer, and fibrin degradation product as biomarkers of rheumatoid arthritis. Sci Rep. 2021;11(1):16903.","journal-title":"Sci Rep"},{"issue":"8","key":"1155_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216246","volume":"80","author":"SX Zhang","year":"2021","unstructured":"Zhang SX, Wang J, Sun HH, et al. Circulating regulatory T cells were absolutely decreased in dermatomyositis\/polymyositis patients and restored by low-dose IL-2. Ann Rheum Dis. 2021;80(8): e130.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1155_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102645","volume":"19","author":"R Wu","year":"2020","unstructured":"Wu R, Li N, Zhao X, et al. Low-dose Interleukin-2: Biology and therapeutic prospects in rheumatoid arthritis. Autoimmun Rev. 2020;19(10): 102645.","journal-title":"Autoimmun Rev"},{"issue":"24","key":"1155_CR28","doi-asserted-by":"publisher","first-page":"9166","DOI":"10.1073\/pnas.0600240103","volume":"103","author":"MP Rubinstein","year":"2006","unstructured":"Rubinstein MP, Kovar M, Purton JF, et al. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A. 2006;103(24):9166\u201371.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1155_CR29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180\u201390.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"1155_CR30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nri2295","volume":"8","author":"C Dong","year":"2008","unstructured":"Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008;8(5):337\u201348.","journal-title":"Nat Rev Immunol"},{"key":"1155_CR31","doi-asserted-by":"publisher","first-page":"1055466","DOI":"10.3389\/fimmu.2022.1055466","volume":"13","author":"JM Sanders","year":"2022","unstructured":"Sanders JM, Jeyamogan S, Mathew JM, Leventhal JR. Foxp3+ regulatory T cell therapy for tolerance in autoimmunity and solid organ transplantation. Front Immunol. 2022;13:1055466.","journal-title":"Front Immunol"},{"issue":"2","key":"1155_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.immuni.2009.08.001","volume":"31","author":"CE Sutton","year":"2009","unstructured":"Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity. 2009;31(2):331\u201341.","journal-title":"Immunity"},{"issue":"8","key":"1155_CR33","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.4049\/jimmunol.180.8.5167","volume":"180","author":"AV Rachitskaya","year":"2008","unstructured":"Rachitskaya AV, Hansen AM, Horai R, et al. Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol. 2008;180(8):5167\u201371.","journal-title":"J Immunol"},{"issue":"3","key":"1155_CR34","doi-asserted-by":"publisher","first-page":"C714","DOI":"10.1152\/ajpcell.00418.2001","volume":"283","author":"RC Langen","year":"2002","unstructured":"Langen RC, Schols AM, Kelders MC, Van Der Velden JL, Wouters EF, Janssen-Heininger YM. Tumor necrosis factor-alpha inhibits myogenesis through redox-dependent and -independent pathways. Am J Physiol Cell Physiol. 2002;283(3):C714\u201321.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"1155_CR35","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s13075-018-1737-2","volume":"20","author":"Y Ishikawa","year":"2018","unstructured":"Ishikawa Y, Iwata S, Hanami K, et al. Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis. Arthritis Res Ther. 2018;20(1):240.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1155_CR36","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","volume":"53","author":"T Gono","year":"2014","unstructured":"Gono T, Kaneko H, Kawaguchi Y, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford). 2014;53(12):2196\u2013203.","journal-title":"Rheumatology (Oxford)"},{"key":"1155_CR37","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3389\/fimmu.2020.01142","volume":"11","author":"M Zhang","year":"2020","unstructured":"Zhang M, Zhang S. T Cells in fibrosis and fibrotic diseases. Front Immunol. 2020;11:1142.","journal-title":"Front Immunol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01155-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01155-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01155-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T16:29:06Z","timestamp":1698769746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01155-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["1155"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01155-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2413480\/v1","asserted-by":"object"}]},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]},"assertion":[{"value":"25 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of the Second Hospital of Shanxi Medical University (Approval (2019) KY No. (105)).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}